News and Events

Latest News

Stay up to date on Relief activities

Here you will find latest news, upcoming events and interviews.

Corporate News

Archive

Relief Therapeutics Expands U.S. Commercial Team

23 May 2022 | Ad Hoc Announcement pursuant to Art. 53 LR
Relief Therapeutics Files Amendment No. 2 to its Registration Statement on Form 20-F with the U.S. Securities and Exchange Commission

11 May 2022 | Ad Hoc Announcement pursuant to Art. 53 LR
Acer Therapeutics and Relief Therapeutics Announce Presentation of ACER-001 Data at the Genetic Metabolic Dieticians International Conference

6 May 2022 | Ad Hoc Announcement pursuant to Art. 53 LR
Relief Therapeutics Announces Notice of Annual General Meeting of RELIEF THERAPEUTICS Holding SA

6 May 2022 | Ad Hoc Announcement pursuant to Art. 53 LR
Relief Therapeutics' Wholly Owned Subsidiary, APR Applied Pharma Research, Receives Notice of Allowance of Key U.S. Patent Application Covering PKU GOLIKE(R)

27 April 2022 | Ad Hoc Announcement pursuant to Art. 53 LR
Relief Therapeutics Appoints Drew Cronin-Fine as Executive Director, Head of U.S. Marketing

26 April 2022 | Ad Hoc Announcement pursuant to Art. 53 LR
Relief Reports that its U.S. Collaboration Partner has Filed a New Breakthrough Therapy Designation Request for Aviptadil

22 April 2022 | Ad Hoc Announcement pursuant to Art. 53 LR
Acer Therapeutics and Relief Therapeutics Announce Presentation of ACER-001 Data at the Society for Inherited Metabolic Disorders Annual Meeting

12 April 2022 | Ad Hoc Announcement pursuant to Art. 53 LR
Relief Therapeutics Reports Execution of Stipulation with NeuroRx and Jonathan Javitt to Continue Mediation Process

5 April 2022 | Ad Hoc Announcement pursuant to Art. 53 LR
Relief Therapeutics Announces that its Subsidiary was Issued a Swiss Patent Entitled 'Vasoactive Intestinal Peptide (VIP) for the Use in the Treatment of Drug-induced Pneumonitis'

1 April 2022 | Ad Hoc Announcement pursuant to Art. 53 LR

Events and Presentations

H.C. Wainwright Global Investment Conference - May 23 - 26, 2022

Tuesday, May 24, 2022
12:00pm EST

Listen to Webcast

Scientific References

RLF-100™

Media Contact

For media inquiries contact:

Rx Communication Group
Michael Miller
Mail: This email address is being protected from spambots. You need JavaScript enabled to view it.
Tel.: 917.633.6086

Latest News

Corporate News

Archive

Relief Therapeutics Expands U.S. Commercial Team

Relief Therapeutics Files Amendment No. 2 to its Registration Statement on Form 20-F with the U.S. Securities and Exchange Commission

Acer Therapeutics and Relief Therapeutics Announce Presentation of ACER-001 Data at the Genetic Metabolic Dieticians International Conference

Relief Therapeutics Announces Notice of Annual General Meeting of RELIEF THERAPEUTICS Holding SA

Relief Therapeutics' Wholly Owned Subsidiary, APR Applied Pharma Research, Receives Notice of Allowance of Key U.S. Patent Application Covering PKU GOLIKE(R)

Relief Therapeutics Appoints Drew Cronin-Fine as Executive Director, Head of U.S. Marketing

Relief Reports that its U.S. Collaboration Partner has Filed a New Breakthrough Therapy Designation Request for Aviptadil

Acer Therapeutics and Relief Therapeutics Announce Presentation of ACER-001 Data at the Society for Inherited Metabolic Disorders Annual Meeting

Relief Therapeutics Reports Execution of Stipulation with NeuroRx and Jonathan Javitt to Continue Mediation Process

Relief Therapeutics Announces that its Subsidiary was Issued a Swiss Patent Entitled 'Vasoactive Intestinal Peptide (VIP) for the Use in the Treatment of Drug-induced Pneumonitis'

Events and Presentations

H.C. Wainwright Global Investment Conference - May 23 - 26, 2022

Scientific References

RLF-100™

Media Contact

Company

Pipeline

Investor Relations

News and Events